Skeletal Muscle Loss During Neoadjuvant Chemotherapy for Breast Cancer: Diabetes as an Independent Predictor | Synapse
March 26, 2026Open Access
Skeletal Muscle Loss During Neoadjuvant Chemotherapy for Breast Cancer: Diabetes as an Independent Predictor
Key Points
To examine the impact of neoadjuvant chemotherapy on skeletal muscle loss and identify diabetes as a predictor of muscle mass changes.
Analyzed muscle mass changes during neoadjuvant chemotherapy.
Measured skeletal muscle index (SMI) before and after treatment.
Evaluated the role of diabetes mellitus as an independent predictor.
Significant reductions in skeletal muscle and fat observed during treatment.
Increased rates of low skeletal muscle mass (LSMM) noted post-treatment.
Diabetes mellitus strongly correlates with lower SMI after chemotherapy.
Abstract
NACT is associated with significant reductions in skeletal muscle and subcutaneous fat, together with increased rates of LSMM. Diabetes mellitus independently predicted lower post-treatment SMI.